The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2022 | Development of individualized mRNA neoantigen vaccines for pancreatic cancer
Vinod Balachandran, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the challenges of using immunotherapy for pancreatic cancer and explains how investigation of a rare subset of patients who have spontaneous immune activation in primary tumors has led to the development of mRNA neoantigen vaccines for patients who do not undergo spontaneous immune activation. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
